Emergency Medicine
Mass casualty medicine and anesthesia special issue: science and clinical practice.
26 Jan, 2022 | 02:04h | UTCEditorials:
Mass casualty medicine: time for a 21st century refresh
Exercising for mass casualty preparedness
Massive transfusion and severe blood shortages: establishing and implementing predictors of futility
Transfusion support during mass casualty events
Embracing uncertainty in mass casualty incidents
Pre-hospital critical care at major incidents
Provision of pre-hospital medical care for terrorist attacks
Global lessons learned from COVID-19 mass casualty incidents
Reimagining health preparedness in the aftermath of COVID-19
Preparing for mass casualty events despite COVID-19
Paediatric Anaesthesia:
Paediatric patients in mass casualty incidents: a comprehensive review and call to action
Pre-hospital Care:
Injury scoring systems for blast injuries: a narrative review
Preparedness:
Learning from terrorist mass casualty incidents: a global survey
Refining mass casualty plans with simulation-based iterative learning
Specific Incidents:
Mass casualty, intentional vehicular trauma and anaesthesia
Correspondence:
Development and evaluation of a mass casualty medicine simulation method using figurines
RCT: CPAP improved outcomes in patients with acute hypoxemic respiratory failure due to COVID-19, but high-flow nasal oxygen was not better than conventional oxygen therapy.
25 Jan, 2022 | 09:50h | UTCEditorial: Defining Optimal Respiratory Support for Patients With COVID-19 – JAMA
Commentary on Twitter
RCT of patients with acute hypoxemic respiratory failure due to #COVID19 found an initial strategy of CPAP, compared with conventional oxygen therapy, significantly reduced the composite outcome of tracheal intubation or mortality within 30 days. https://t.co/fznFigiFmu pic.twitter.com/b7mHssbfkp
— JAMA (@JAMA_current) January 24, 2022
New CPR guidance addresses more contagious COVID-19 variants amidst evolving pandemic.
25 Jan, 2022 | 09:48h | UTCNews release: New CPR guidance addresses more contagious COVID-19 variants amidst evolving pandemic – American Heart Association
RCT: Fentanyl vs. placebo with ketamine and rocuronium for patients undergoing rapid sequence intubation in the emergency department.
25 Jan, 2022 | 09:14h | UTCFentanyl versus placebo with ketamine and rocuronium for patients undergoing rapid sequence intubation in the emergency department: the FAKT study – a randomized clinical trial – Academic Emergency Medicine (link to abstract – $ for full-text)
Updated Guideline: Recommended drugs and biologics in adult patients with COVID-19.
24 Jan, 2022 | 08:52h | UTC
Commentary on Twitter (thread – click for more)
https://twitter.com/ASPphysician/status/1484874519252721664
A guide to immunotherapy for COVID-19.
24 Jan, 2022 | 08:29h | UTCA guide to immunotherapy for COVID-19 – Nature Medicine
The WSES/SICG/ACOI/SICUT/AcEMC/SIFIPAC guidelines for diagnosis and treatment of acute left colonic diverticulitis in the elderly.
24 Jan, 2022 | 08:24h | UTCRelated:
ACP Guideline: Diagnosis and management of acute left-sided colonic diverticulitis.
Review: Changing paradigms in the management of acute uncomplicated diverticulitis.
Review: Elective surgical management of diverticulitis
State of the Art Review | Management of colonic diverticulitis
Drains, germs, or steel: Multidisciplinary management of acute colonic diverticulitis
Systematic review: Management of colonic diverticulitis
WSES Guidelines for the Management of Acute Colonic Diverticulitis
ASCRS Guidelines for the Treatment of Left-Sided Colonic Diverticulitis
Perioperative guidelines on antiplatelet and anticoagulant agents: 2022 Update.
21 Jan, 2022 | 09:53h | UTC
M-A: In comatose survivors of cardiac arrest, targeted hypothermia is not associated with improved survival or better neurological outcomes vs. targeted normothermia.
21 Jan, 2022 | 09:29h | UTCRelated:
RCT: In non–critically ill hospitalized patients with COVID-19, the use of a P2Y12 Inhibitor (ticagrelor in 63% of patients and clopidogrel in 37%) in addition to a therapeutic dose of heparin did not improve survival free of organ support compared to therapeutic heparin alone.
19 Jan, 2022 | 08:56h | UTCEditorial: Antiplatelet Therapy in Patients With COVID-19—More Is Less? – JAMA
Commentary: Adding a P2Y12 Inhibitor Does Not Improve Outcomes in COVID-19 – HealthDay
RCT: In critically ill adults, using a balanced multielectrolyte solution did not lower the risk of death or acute kidney injury compared to standard saline.
19 Jan, 2022 | 08:41h | UTCBalanced Multielectrolyte Solution versus Saline in Critically Ill Adults – New England Journal of Medicine (link to abstract – $ for full-text)
Related:
Commentary on Twitter
https://twitter.com/NEJM/status/1483540959518281730
M-A: Evaluation of interventions to reduce opioid prescribing for patients discharged from the emergency department.
19 Jan, 2022 | 08:13h | UTCInvited commentary: Optimizing Opioid Prescriptions for Patients in the Emergency Department—How Much Is Almost Never? – JAMA Network Open
Commentary on Twitter
This meta-analysis of 63 studies showed that most interventions were able to reduce opioid prescription rates but not the prescribed opioid quantity for ED-discharged patients. Almost no data on patients-centered outcomes were assessed in these studies. https://t.co/Cd1D7EjCkI
— JAMA Network Open (@JAMANetworkOpen) January 13, 2022
COVID-19 updated evidence: a Cochrane round-up.
18 Jan, 2022 | 09:53h | UTCCOVID-19 evidence: a Cochrane round-up – Cochrane Library
ACP Guideline: Diagnosis and management of acute left-sided colonic diverticulitis.
18 Jan, 2022 | 09:38h | UTCRelated Systematic Reviews:
Annals Video Summary: Diagnostic Imaging and Medical Management of Acute Left-Sided Colonic Diverticulitis: A Systematic Review – Annals of Internal Medicine
News Release: ACP releases two new clinical guidelines on the diagnosis and management of diverticulitis – American College of Physicians
WHO recommends two new drugs (Baricitinib and Sotrovimab) to treat COVID-19.
17 Jan, 2022 | 00:48h | UTCNews release: WHO recommends two new drugs to treat COVID-19 – World Health Organization
Infographic with the updated recommendations: A living WHO guideline on drugs for covid-19 – The BMJ
Commentaries:
Commentary on Twitter (thread – click for more)
WHO has also conditionally recommended the use of sotrovimab for treating mild or moderate #COVID19 in patients who are at high risk of hospitalization: patients who are older, immunocompromised, with underlying conditions & those unvaccinated https://t.co/UAc21Wgxbl https://t.co/Z39mSKrOv5
— World Health Organization (WHO) (@WHO) January 14, 2022
Viewpoint: COVID-19 therapeutics for nonhospitalized patients.
17 Jan, 2022 | 00:31h | UTCCOVID-19 Therapeutics for Nonhospitalized Patients – JAMA
Editorial: Realizing the Potential of Anti–SARS-CoV-2 Monoclonal Antibodies for COVID-19 Management – JAMA
Multi-Disciplinary Guideline: Management of nephrolithiasis in pregnancy.
16 Jan, 2022 | 23:17h | UTC
Commentary from the author on Twitter
https://t.co/bFtOYFgBmr Started as an assigned resident presentation. Turned into a set of multi-d guidelines implemented at the university level. Now published for all to reference! Thank you all authors for input & guidance @peepeeDoctor @willrobe1 @amy_krambeck @sapanambani
— Matthew Lee (@MSLee_MD) December 23, 2021
RCT: In patients undergoing emergency endotracheal intubation, 7-day survival was significantly lower with etomidate vs. ketamine (77.3% versus 85.1%), but 28 survival rates were not significantly different (etomidate 64.1% vs. ketamine 66.8%, p = 0.294).
16 Jan, 2022 | 23:09h | UTC
Commentary on Twitter
Etomidate vs ketamine for emergency endotracheal intubation, RCT
💉801 critically ill pts assigned to receive etomidate (0.2–0.3 mg/kg) or ketamine (1–2 mg/kg)
💉day 7 survival significantly lower with etomidate
💉no significantly different day 28 survivalhttps://t.co/CkxufORC8A pic.twitter.com/xQ4AtCifc7— Intensive Care Medicine (@yourICM) December 17, 2021
Fluvoxamine for Covid-19: What Prescribers and Pharmacists Need to Know.
14 Jan, 2022 | 08:37h | UTCFluvoxamine: What Prescribers and Pharmacists Need to Know – Covid-19 Advisory for Ontario
Related:
Fluvoxamine for the early treatment of SARS-CoV-2 Infection: a review of current evidence.
Commentary on Twitter
Thinking of prescribing fluvoxamine for covid 19? Ontario has a nice infographichttps://t.co/MKT8PqlJpM
— Todd C. Lee (@DrToddLee) January 12, 2022
AAN Position Statement: Consent Issues in the Management of Acute Ischemic Stroke.
14 Jan, 2022 | 08:24h | UTCConsent Issues in the Management of Acute Ischemic Stroke: AAN Position Statement – Neurology
News Release: Who gives consent for treatment when a person with stroke cannot? – American Academy of Neurology
Systematic Review: Restrictive transfusion thresholds can safely decrease transfusions by 41% across a broad range of clinical contexts.
14 Jan, 2022 | 08:18h | UTCTransfusion thresholds for guiding red blood cell transfusion – Cochrane Library
Related:
Research: Restrictive or Liberal Red-Cell Transfusion for Cardiac Surgery
Transfusion Requirements After Cardiac Surgery: The TRACS Randomized Controlled Trial – JAMA
Commentary on Twitter
https://twitter.com/cochraneINJ/status/1473667822542888964
RCT: Early Remdesivir in outpatients can prevent progression to severe Covid-19.
13 Jan, 2022 | 08:54h | UTCEditorial: The Goldilocks Time for Remdesivir — Is Any Indication Just Right?
Commentary: Three days of remdesivir cuts risk for severe COVID-19 in outpatients – MedicalXpress
Commentary on Twitter
Among nonhospitalized patients with Covid-19–related symptoms, a 3-day course of remdesivir resulted in an 87% lower risk of hospitalization or death than placebo. #COVID19 #IDTwitter https://t.co/YFflw5nBxB pic.twitter.com/4NCD9AcnYH
— NEJM (@NEJM) December 22, 2021
Another study showed neutralizing monoclonal antibody therapies are not effective when given after the patient is already hospitalized.
13 Jan, 2022 | 08:48h | UTCInvited Commentary: Time to knock monoclonal antibodies off the platform for patients hospitalised with COVID-19
Cohort Study: Patient factors associated with appendectomy within 30 days of initiating antibiotic treatment for appendicitis – the presence of an appendicolith was associated with a nearly 2-fold increased risk of undergoing appendectomy within 30 days.
13 Jan, 2022 | 08:39h | UTCPatient Factors Associated With Appendectomy Within 30 Days of Initiating Antibiotic Treatment for Appendicitis – JAMA Surgery (free for a limited period)
Invited commentary: Appendicoliths, Antibiotic Treatment Failure, and Appendectomy—Is the Glass Half Full or Half Empty? – JAMA Surgery
The COVID-19 Treatment Guidelines Panel’s Statement on Anticoagulation in Hospitalized Patients With COVID-19 – in the absence of contraindications, use therapeutic-dose anticoagulation with low molecular weight heparin for hospitalized patients not in the ICU who have a D-dimer above the upper limit of normal.
12 Jan, 2022 | 09:11h | UTC


